ArticlePharmaceuticals (Basel, Switzerland)2024

Assessment of Patient-Reported Outcomes at 48 Months of Treatment with Dupilumab for Severe Atopic Dermatitis: A Single-Center Real-Life Experience with 126 Patients.

Francesca Barei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.